Cambridge Healthtech Institute’s Third Annual 

Predictive Preclinical Models in Oncology 

Modeling for Targeted and Immune-Mediated Therapy Assessment

February 16-18, 2015 | Moscone North Convention Center | San Francisco, CA
Part of the 22nd Annual Molecular Medicine Tri-Conference

 

Predicting whether a potential new anticancer agent will be effective in patients remains a challenge. Despite tremendous progress in our understanding of cancer biology, the majority of novel anticancer therapies fail in Phase III clinical trials. This situation brings into question the quality of preclinical tumor models and predictability of preclinical studies in oncology. There is a critical need for models and approaches that allow to more effectively evaluate novel cancer therapeutics as well as to identify predictive biomarkers early in drug development. CHI’s Third Annual Predictive Preclinical Models in Oncology is designed to highlight the cutting-edge in vitro and in vivo preclinical tumor models and to facilitate a discussion about effective translational approaches in cancer research.


ADVANCES IN TUMOR MODELING=ADVANCES IN CANCER DRUG DISCOVERY AND DEVELOPMENT

Assessing The Predictive Value of Preclinical Cancer Models

Alexander Kamb, Ph.D., Senior Vice President, Discovery Research, Amgen

Targeting Developmental Pathways in Cancer

Frederic de Sauvage, Ph.D., Vice President, Molecular Oncology, Genentech

Preclinical Trials in Mouse Models of Brain Tumors

Eric C. Holland, M.D., Ph.D., Senior Vice President, Director, Division of Human Biology, Solid Tumor Translational Research, Nancy and Buster Alvord Brain Tumor Center, Fred Hutchinson Cancer Research Center, University of Washington

Microenvironmental Regulation of GBM Progression and Therapeutic Resistance

Gabriele Bergers, Ph.D., Professor of Neurological Surgery, Neill H. and Linda S. Brownstein Endowed Chair in Brain Tumor Research, Principal Investigator, Brain Tumor Research Center, University of California, San Francisco

Towards Personalized Medicine: Companion Therapeutics in the I-SPY 2 TRIAL

Laura J. van ‘t Veer, Ph.D., Professor of Laboratory Medicine, University of California San Francisco; Leader, Breast Oncology Program; Associate Director, Applied Genomics, UCSF Helen Diller Family


TRANSLATIONAL APPROACHES IN CANCER IMMUNOTHERAPY DEVELOPMENT

Biomarkers in Cancer Immunotherapy

Ira Mellman, M.D., Vice President, Cancer Immunology, Genentech

Strategies for Clinical Development of Cancer Immunotherapy

Roy Baynes, M.D., Senior Vice President Global Clinical Development, Merck

Translational Strategies for the Clinical Development of Immunomodulatory Antibodies

Robert Pierce, M.D., CMO, OncoSec Medical, Inc.

Preclinical Validation of Immunotherapies and Combination Strategies for Cancer

James Smothers, Ph.D., Senior Director, Head, Discovery, Immuno-Oncology & Combinations DPU, Oncology R&D, GlaxoSmithKline


UNFOLDING CANCER IMMUNOTHERAPY MECHANISMS

Inflammation and Cancer: Immune Cells as Targets For Anti-Cancer Therapy

Lisa M. Coussens, Ph.D., Professor and Chair, Director, Basic Research, Department of Cell & Developmental Biology, Knight Cancer Institute, Oregon Health & Sciences University

Criteria for Identifying Responses to Cancer Immunotherapy

Alan L. Epstein, M.D., Ph.D., Department of Pathology, USC Keck School of Medicine, Los Angeles

How to Unleash Anti-Tumor Immunity by Modulating the PI3K Pathway

Khaled Ali, Ph.D., Senior Scientist, Amgen Oncology


TRANSLATIONAL APPROACHES TO CHILDHOOD CANCER

Preclinical Childhood Cancer Models for Developing Molecularly Targeted Therapies.

Peter Houghton, Ph.D., Director, Center for Childhood Cancer, The Research Institute, Nationwide Children’s Hospital

The Institutes for Molecular Medicine at Phoenix Children’s Hospital to Address the Unmet Need: Slow Progress in Pediatric Drug Development

Nazneen Aziz, Ph.D., Senior Vice President & Chief Research Officer, Phoenix Children's Hospital


3D MODELS AND THEIR APPLICATIONS

Evaluating Lymphocyte Redirection and Recruitment Using a Novel 3D Lung Tumor Model System

David Colter, Ph.D., Principal Scientist, Biologics Research, Janssen


ADVANCES IN MODELING AND MODELS’ APPLICATIONS

Preclinical Models of Human Cancer at the Center for Advanced Preclinical Research (CAPR): Quantitative Methods for Assaying Drug Efficacy and Resistance

Philip Martin, Ph.D., D.V.M., Veterinary Pathologist, Center for Advanced Preclinical Research (CAPR), Frederick NationalLeidos Biomedical/Laboratory for Cancer Research

Validation of a Tumor Antigen Also Expressed on Subsets of Activated Lymphocytes as a T Cell Engager BiTE® Therapy Target

Olivier P. Nolan-Stevaux, Ph.D., Senior Scientist, Department of Oncology, Amgen, Inc.



 

Patient Derived Xenograft Clinical Trial Program

Neal Goodwin, Ph.D., Vice President, Corporate Research and Development, Champions Oncology


 

Additional Presentation Sponsored by


Luncheon Presentation Sponsored by



Suggested Event Package:

February 16 Morning Short Course: Using PDX and Other Preclinical Models in Oncology to Inform First-Man-Trial Design: Tools and Techniques

February 19-20 Symposia: Cancer Immunotherapy 



For more details on the conference, please contact:
Marina Filshtinsky, M.D.
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5406
E: mfilshtinsky@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

Joseph Vacca (Companies L-Z) 
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com 

 

  2015 Plenary Sessions 

2015 MMTC Prelim Agenda 

Premier Sponsors:

Elsevier 


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Singulex 

Thomson Reuters-Large 


Local Partners:

BayBio 


biocube 


Cabs 

City of SSF